Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05323955
Title Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (BRIDGET)
Acronym BRIDGET
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Carey Anders, M.D.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
University of Michigan Health System RECRUITING Ann Arbor Michigan 48109 United States Details
Washington University in St. Louis RECRUITING Saint Louis Missouri 63130 United States Details
Duke University Medical Center RECRUITING Durham North Carolina 27710 United States Details
Ohio State University Comprehensive Cancer Center RECRUITING Columbus Ohio 43210 United States Details
Providence Portland Medical Center RECRUITING Portland Oregon 97213 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field